PONVORY™ complements today's evolvingneeds1-5
Onboarding steps made convenient1:
No known food
Flexible patient management1:
as seen in
See more information about
the reversibility of PONVORY™.
Before initiation of treatment with PONVORY™, assess the following based on individual patient needs: complete blood count, cardiac evaluation, liver function tests, ophthalmic evaluation, current or prior medications with immune system effects, and vaccinations.1
PD = pharmacodynamic; PK = pharmacokinetic.
For select patients, first-dose monitoring is recommended1
Because initiation of PONVORY™ treatment results in a decrease in heart rate (HR), with1:first-dose, 4-hour monitoring is recommended for patients
- Sinus bradycardia (HR <55 beats per minute [bpm])
- First- or second-degree atrioventricular (AV) block (Mobitz type I)
- History of myocardial infarction or heart failure occurring >6 months prior to treatment initiation and in stable condition
For select patients who require first-dose monitoring1:
ADMINISTER the first dose of PONVORY™ in a setting where resources to appropriately manage symptomatic bradycardia are available
MONITOR patients for 4 hours after the first dose for signs and symptoms of bradycardia with a minimum of hourly pulse and blood pressure measurements
OBTAIN an ECG in these patients prior to dosing and at the end of the 4-hour observation period
For more detailed information about first-dose monitoring,
please see Section 2.3 in the PONVORY™ full Prescribing Information.
Before initiation of treatment with PONVORY™, assess the following1:
AV = atrioventricular; CBC = complete blood count; ECG = electrocardiogram; MS = multiple sclerosis; VZV = varicella-zoster virus.